Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2009 (2009), Article ID 867678, 13 pages
Research Article

Molecular Characterization of the Tumor Suppressor Candidate 5 Gene: Regulation by PPAR and Identification of TUSC5 Coding Variants in Lean and Obese Humans

1Obesity & Metabolism Research Unit, USDA-Agricultural Research Service Western Human Nutrition Research Center, Davis, CA 95616, USA
2Department of Biological Sciences, Department of Biophysics and Chemical Biology, Seoul National University, Seoul 151-742, South Korea
3Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Canada K1H 8L1
4Graduate Schools of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan
5Department of Pathology, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60208, USA
6Division of Advanced Therapeutics for Metabolic Diseases, Tohoku University Graduate School of Medicine, Sendai 980-8576, Japan
7Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA
8Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
9Institute National de la Santé et de la Recherche Médicale (INSERM) UMR 626, 13385 Marseille and Faculté de Médecine, Université de la Méditerranée, Marseille, France
10Department of Nutrition, University of California, Davis 95616, USA

Received 28 August 2009; Accepted 13 November 2009

Academic Editor: Dipak Panigrahy

Copyright © 2009 Trina A. Knotts et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Tusc5 protein abundances were measured in 3T3-L1 adipocytes or human subcutaneous white adipose tissue (WAT) after PPARγ agonist treatment. Supplementary Figure 1: Treatment of Mature Murine 3T3-L1 Adipocytes with the PPARγ Agonist GW1929 or Troglitazone (Trog) Increases Tusc5 Protein Abundance. Cells treated in parallel with those used for dose-response studies depicted in Figure 1 of the manuscript were used to isolate protein and perform Western blot analysis (see Methods). Both GW1929 and Trog increased Tusc5 protein expression. Blot depicts results from n= 2 samples/treatment and is representative of the experiment. Supplementary Figure 2: Tusc5 Protein Expression in Subcutaneous WAT is Unchanged by >11 Wk of Pioglitazone (PIO) Treatment in Type 2 Diabetic Adults. WAT samples available from a subset of subjects for whom gene expression analyses were performed (see Figure 3 in the manuscript) were used for Western blot determination of Tsuc5 protein abundance before and after treatment with placebo or PIO. Wide person-to-person variability in Tusc5 protein levels was observed, and no effect of PIO treatment was apparent, consistent with mRNA patterns (see Figure 3 in manuscript).

  1. Supplementary Material